Simplify Logo
LFB

LFB

Public health biopharmaceuticals via plasma-derived products

MES Administrator

Full-Time
No salary listed
Mid
Bachelor's
Arras, France
Hybrid

Up to two remote-work days per week after four months of seniority.

About the job

Requirements
  • Higher education qualification at Bac+2 to Bac+5 level in industrial computing.
  • Approximately five years of successful experience in industrial process programming, preferably in the pharmaceutical industry.
  • Knowledge of Manufacturing Execution Systems, with Siemens Opcenter Execution Pharma expertise considered an advantage.
  • Project-management skills covering studies through commissioning.
  • Knowledge of project-management tools, including Excel and Microsoft Project.
  • Knowledge of the regulatory environment applicable to the pharmaceutical industry, including qualification procedures, Good Manufacturing Practices, and 21 CFR Part 11.
Responsibilities
  • Administer the MES and maintain the site's installation in operational condition in accordance with established procedures.
  • Analyze process or IT malfunctions, provide technical expertise to internal clients, clarify problematic situations, and propose solutions.
  • Design, develop, and participate in the qualification of systems.
  • Respect equipment availability and reliability rules and targets.
  • Contribute to projects by participating in technical orientations through expertise and helping develop technical specifications with new-construction and engineering departments.
  • Participate in the site's MES on-call duties.
Desired Qualifications
  • Basic knowledge of instrumentation.
  • Experience in maintenance.
  • Experience in the pharmaceutical industry.
  • Siemens OpCenter Execution Pharma expertise.

About the company

LFB is a French biopharmaceutical company that develops and manufactures medicines from plasma and biotech products. It collects plasma, fractionates it into medicines, and also produces recombinant proteins for rare diseases in immunology and hemostasis, sold in many countries. It stands out because it started as a state-initiated public health mission and remains state-owned with the French State as sole shareholder, plus vertical integration through acquisitions of plasma collection firms. Its goal is to ensure a reliable supply of essential medicines for public health while growing as a global biopharma player.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Courcebœufs, France

Founded

1994

Get referred to LFB

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Arras released first medicines in 2025, proving commercialization after heavy capital spending.
  • LFB signed a 2026 collaboration with Sartorius to accelerate client programs and GMP manufacturing.
  • France 2030 funding and the 2026 Alès expansion add capacity and roughly fifty jobs.

What critics are saying

  • EFS must raise plasma collections to 1.4 million liters by 2028 or Arras underutilizes.
  • LFB BIOMANUFACTURING still depends on Sartorius for cell line development, limiting full-stack control.
  • A single French industrial base creates existential exposure to contamination, recalls, or regulatory shutdowns.

What makes LFB unique

  • French state-owned sole domestic plasma fractionator anchors national medicine supply.
  • Arras plant, authorized in 2025, centralizes production and triples plasma-derived capacity.
  • Europlasma and Amber Plasma give LFB 24 Central European collection centers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Hybrid Work Options

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Stock Options

Company Equity

Conference Attendance Budget

Family Planning Benefits

Fertility Treatment Support

Professional Development Budget

Education allowance

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

7%

1 year growth

7%

2 year growth

6%
MyPharma Editions
May 30th, 2024
LFB Acquires Amber Plasma in Czech Republic

Title: "LFB Acquires Amber Plasma in the Czech Republic" LFB and its subsidiary Europlasma have acquired Amber Plasma, which operates 12 plasma collection centers in the Czech Republic. This acquisition increases Europlasma's total to 24 centers in Central Europe, enhancing LFB's plasma collection capacity. The move supports LFB's goal to meet growing patient demand and will aid in the launch of a new production site in Arras, France, tripling its medication production capacity.